← Back to Screener
Fennec Pharmaceuticals Inc. Common Stock (FENC)
Price$6.30
Favorite Metrics
Price vs S&P 500 (26W)-33.49%
Price vs S&P 500 (4W)-18.81%
Market Capitalization$217.19M
All Metrics
P/CF (Annual)8.12x
Book Value / Share (Quarterly)$1.04
P/TBV (Annual)5.91x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)207.19%
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)-18.23%
Gross Margin (TTM)92.01%
Net Profit Margin (TTM)-18.83%
EPS (TTM)$-0.33
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-0.33
Revenue Growth (5Y)204.69%
EPS (Annual)$-0.34
ROI (Annual)-27.46%
Gross Margin (Annual)91.57%
Net Profit Margin (5Y Avg)-2458.16%
Cash / Share (Quarterly)$1.08
Revenue Growth QoQ (YoY)73.84%
ROA (Last FY)-13.81%
Revenue Growth TTM (YoY)-26.40%
EBITD / Share (TTM)$-0.29
ROE (5Y Avg)-70.75%
Operating Margin (TTM)-15.93%
Cash Flow / Share (Annual)$-0.37
P/B Ratio6.12x
P/B Ratio (Quarterly)7.41x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.16x
Net Interest Coverage (TTM)-6.24x
ROA (TTM)-18.46%
EV / EBITDA (TTM)66.11x
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)6.37x
Quick Ratio (Quarterly)5.87x
3-Month Avg Trading Volume0.17M
52-Week Price Return23.34%
EV / Free Cash Flow (Annual)7.99x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.39
P/S Ratio (Annual)4.87x
Asset Turnover (Annual)0.63x
52-Week High$9.92
Operating Margin (5Y Avg)-2412.74%
EPS Excl Extra (Annual)$-0.34
26-Week Price Return-29.50%
Quick Ratio (Annual)5.87x
13-Week Price Return-14.70%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.37x
Enterprise Value$180.406
Revenue / Share Growth (5Y)193.28%
Asset Turnover (TTM)0.63x
Book Value / Share Growth (5Y)-6.51%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.87x
Pretax Margin (Annual)-21.58%
Cash / Share (Annual)$1.08
3-Month Return Std Dev63.15%
Net Income / Employee (TTM)$-0
ROE (Last FY)-27.46%
Net Interest Coverage (Annual)-6.24x
EPS Basic Excl Extra (Annual)$-0.34
Receivables Turnover (TTM)1.94x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.33
Receivables Turnover (Annual)2.47x
ROI (TTM)-13.50%
P/S Ratio (TTM)6.21x
Pretax Margin (5Y Avg)-2457.96%
Revenue / Share (Annual)$1.56
Tangible BV / Share (Annual)$7.48
Forward P/E48.00x
Price vs S&P 500 (52W)-6.49%
Year-to-Date Return-15.58%
5-Day Price Return1.56%
EPS Normalized (Annual)$-0.34
ROA (5Y Avg)-47.99%
Net Profit Margin (Annual)-21.82%
Month-to-Date Return5.69%
Cash Flow / Share (TTM)$-0.53
EBITD / Share (Annual)$-0.29
Operating Margin (Annual)-18.60%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-65.46%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.33
P/TBV (Quarterly)15.62x
P/B Ratio (Annual)7.41x
Inventory Turnover (TTM)2.87x
Pretax Margin (TTM)-18.53%
Book Value / Share (Annual)$1.04
Price vs S&P 500 (13W)-15.39%
Beta0.94x
P/FCF (Annual)8.05x
Revenue / Share (TTM)$1.12
ROE (TTM)-13.50%
52-Week Low$4.98
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.25
4.23
4.23
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FENCFennec Pharmaceuticals Inc. Common Stock | 6.21x | -26.40% | 92.01% | — | $6.30 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Fennec Pharmaceuticals is a biopharmaceutical company commercializing PEDMARK, a novel formulation designed to prevent cisplatin-induced hearing loss in children undergoing chemotherapy. The company addresses a significant side effect of cancer treatment with a first-in-class therapeutic approach. Operations are based in the United States.